ArticleOncotarget2017

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study.

Alba A Brandes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.